Role of PD‐L1 Expression in Non‐Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
Background: The latest immunotherapy, used in the treatment of non-small cell lung cancer (NSCLC), uses monoclonal antibodies directed against programmed death ligand 1 (PD-L1) to inhibit its interaction with the PD-1 receptor. Elevated levels of PD-L1 expression were observed on NSCLC cells. The association between PD-L1 expression and clinicopathological features is still unclear. Therefore, we examined this relationship and also compare PD-L1 expression levels with Ki-67, p63 and TTF-1. Methods: 866 samples of NSCLCs were used to prepare tissue microarrays (TMAs) on which immunohistochemical (IHC) reactions were performed. Changes in the level of CD274 (PD-L1) gene expression in 62 NSCLC tumors were tested in relation to 14 normal lung tissues by real-time PCR reactions (RT-PCR). Results: PD-L1 expression was observed in 32.6% of NSCLCs. PD-L1 expression was increased in higher malignancy grades (G) (p < 0.0001) and in higher lymph node status (pN) (p = 0.0428). The patients with low PD-L1 expression had longer overall survival compared to the group with high expression (p = 0.0332) in adenocarcinoma (AC) only. Conclusions: PD-L1 expression seems to be associated with increased tumor proliferation and aggressiveness as well as shorter patient survival in NSCLC, predominantly in the AC group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, anti‐PD‐1/PD‐L1 antibodies can promote T cell activation and enhance anti‐tumor immunity by blocking the interaction between PD‐1 and PD‐L1/PD‐L2 [270, 271].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [271]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Some tumors express PD‐L1, which contributes to immune evasion by inhibiting cytotoxic responses.”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [271]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 1×
“The estimation of PD-L1 expression was performed using the Tumor Proportion Score (TPS) that is applied routinely in diagnostic settings [4,27,28].”
MethodLung Cancer: Epidemiology, Etiology, and Prevention
Dela Cruz, C. S., Tanoue, L. T., & Matthay, R. A. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.09.001 · Cited by 2,484 · cited 1×
“According to the American Cancer Society, the number of deaths from lung cancer is higher than the number of deaths caused by breast, colon and prostate cancers [1].”
BackgroundRemmele, W., & Stegner, H.-E. (1987) · PubMed · Cited by 1,976
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J., Chirieac, L. R., D'Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,303
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791 · cited 1×
“The first effect is inhibition of interleukin 2 (IL-2) synthesis [8].”
BackgroundProgrammed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755 · cited 1×
“In our cohort, involving a Western population, the incidence was lower, which is similar to other studies on this ethnic group [12,16,24] Another explanation for diverse expression of PD-L1 in NSCLC may be related to the use of different scoring methods and cut-off levels for evaluation.”
ResultKonishi, J., Yamazaki, K., Azuma, M., Kinoshita, I., Dosaka-Akita, H., & Nishimura, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0428 · Cited by 678
Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 645
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Guven, D. C., Sahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., Aksoy, S., & Yalcin, S. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1039121 · Cited by 214
“Other than PD-L1 expression in non-small cell lung cancer (Pawelczyk et al., 2019), gastric cancer (Fuchs et al.”
BackgroundZhou, C., Wei, W.-F., Ma, J., Yang, Y., Liang, L.-J., Zhang, Y., Wang, Z., Chen, X., Huang, L., Wang, W., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.034 · Cited by 158
Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
Šutić, M., Vukić, A., Baranašić, J., Försti, A., Džubur, F., Samaržija, M., Jakopović, M., Brčić, L., & Knežević, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111102 · Cited by 150
Galvano, A., Gristina, V., Malapelle, U., Pisapia, P., Pepe, F., Barraco, N., Castiglia, M., Perez, A., Rolfo, C. D., Troncone, G., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100124 · Cited by 144
“Nonetheless, the clinical utility of TMB as a biomarker together with PD-L1 evaluation remains an enigma further complicated by the variety of measuring assays and algorithms.(15-19) Interestingly, no significant association between PD-L1 expression and TMB has been observed,(20) even when comparing the results obtain…”
ResultOh, S. Y., Kim, S., Keam, B., Kim, T. M., Kim, D., & Heo, D. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-99311-y · Cited by 136
Immune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Pennycuick, A., TEIXEIRA, V. H., AbdulJabbar, K., Raza, S. E. A., Lund, T., Akarca, A. U., Rosenthal, R., Kalinke, L., Chandrasekharan, D. P., Pipinikas, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1366 · Cited by 101
Hussain, S. H., Huertas, C. S., Mitchell, A., Deman, A., & Laurenceau, E. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113770 · Cited by 80
Parakh, S., Ernst, M., & Poh, A. R. (2021) · Cancers · doi:10.3390/cancers13246228 · Cited by 80
Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 82
“PD-L1 expression also appears to be associated with increased tumor proliferation and aggressiveness, as well as shorter survival times for patients diagnosed with lung adenocarcinoma [18].”
BackgroundBrodská, B., Otevřelová, P., Šálek, C., Fuchs, O., Gašová, Z., & Kuželová, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112823 · Cited by 71
Song, N., Li, P., Song, P., Li, Y., Zhou, S., Su, Q., Li, X., Yu, Y., Li, P., Feng, M., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00540 · Cited by 55
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia
Mitsudomi, T., Tan, D. S. W., Yang, J. C., Ahn, M., Batra, U., Cho, B. C., Cornelio, G., Lim, T. K. H., Mok, T. S. K., Prabhash, K., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.021 · Cited by 57
Parvathareddy, S. K., Siraj, A. K., Al-Badawi, I. A., Tulbah, A. M., Al‐Dayel, F., & Al-Kuraya, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-83276-z · Cited by 56
Ahmadvand, N., Khosravi, F., Lingampally, A., Wasnick, R. M., Vazquez‐Armendariz, A. I., Carraro, G., Heiner, M., Rivetti, S., Lv, Y., Wilhelm, J., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.04168-2020 · Cited by 54
“PD-L1 expression is also increased in adenocarcinoma and appears to be correlated with elevated tumour proliferation and aggressiveness [14, 16, 25, 27, 28].”
The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
Holder, J. E., Ferguson, C., Oliveira, E., Lodeiro, C., Trim, C. M., Byrne, L. J., Bértolo, E., & Wilson, C. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1154318 · Cited by 56
“Frontiers in Oncology 03 levels have been observed in NSCLC (28).”
BackgroundPD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies
Nishimura, C., Pulanco, M. C., Cui, W., Lu, L., & Zang, X. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.10.004 · Cited by 48
Shinchi, Y., Komohara, Y., Yonemitsu, K., Sato, K., Ohnishi, K., Saito, Y., Fujiwara, Y., Mori, T., Shiraishi, K., Ikeda, K., et al. (2019) · Cancer Science · doi:10.1111/cas.14128 · Cited by 44
Upadhya, A., Yadav, K. S., & Misra, A. R. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1825377 · Cited by 39
Exploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, D., Zaheer, S., Sureka, N., Trisal, M., Chaurasia, J. K., & Zaheer, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155864 · Cited by 41
Liu, Y., Xu, Y., Cheng, X., Lin, Y., Jiang, S., Yu, H., Zhang, Z., Lu, L., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862084 · Cited by 41
Reliable Detection of Extracellular PD-L1 by DNA Computation-Mediated Microfluidics
Zhang, Y., Wu, Q., Huang, Y., Wang, W., Lu, Y., Kang, S., Yang, C. J., & Song, Y. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c01686 · Cited by 33
Lee, S. E., Kim, Y. J., Sung, M., Lee, M.-S., Han, J., Kim, H. K., & Choi, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194794 · Cited by 33
He, J., Pan, Y., Guo, Y., Li, B., & Tang, Y. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000315 · Cited by 32
Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma
Reiniger, L., Téglási, V., Pipek, O., Rojkó, L., Glasz, T., Vágvölgyi, A., Kovalszky, I., Gyulai, M., Lohinai, Z., Rásó, E., et al. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1598575 · Cited by 31
“reflect to greater tendency to necrosis caused by more aggressive tumor phenotype and higher proliferation rate as it was described in a very recent study [20].”
ResultVrankar, M., Kern, I., & Stanič, K. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01696-z · Cited by 32
“This might explain the findings of those studies that associate prevalence of PD-L1 expression with higher stages [12, 13, 28, 39].”
BackgroundSiraj, A. K., Parvathareddy, S. K., Pratheeshkumar, P., Divya, S. P., Al-Sobhi, S. S., Al‐Dayel, F., & Al-Kuraya, K. S. (2021) · Cancers · doi:10.3390/cancers13030555 · Cited by 35
Alföldi, R., Balog, J. Á., Faragó, N., Halmai, M., Kotogány, E., Neuperger, P., Nagy, L. I., Fehér, L. Z., Szebeni, G. J., & Puskás, L. G. (2019) · Cells · doi:10.3390/cells8091093 · Cited by 35
CHEN, W.-T., Chen, C., Su, H.-T., Yueh, P., Hsu, F., & Chiang, I. (2021) · Anticancer Research · doi:10.21873/anticanres.14893 · Cited by 28
Grodzka, A., Knopik-Skrocka, A., Kowalska, K., Kurzawa, P., Krzyżaniak, M., Stencel, K. M., & Bryl, M. (2023) · EXCLI journal · doi:10.17179/excli2023-6122 · Cited by 48
Gavrilov, S. V., Zhudenkov, K., Helmlinger, G., Dunyak, J., Peskov, K. V., & Aksenov, S. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12578 · Cited by 27
Nakahama, K., Kaneda, H., Osawa, M., Izumi, M., Yoshimoto, N., Sugimoto, A. K., Nagamine, H., Ogawa, K., Matsumoto, Y., Sawa, K., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14560 · Cited by 41
Johnson, M. L., Strauss, J. F., Patel, M. R., Garon, E. B., Eaton, K. D., Neskorik, T., Morin, J., Chao, R. C., & Halmos, B. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.01.013 · Cited by 28
Ullah, A., Pulliam, S., Karki, N. R., Khan, J., Jogezai, S., Sultan, S., Muhammad, L., Khan, M., Jamil, N., Waheed, A., et al. (2022) · Clinics and Practice · doi:10.3390/clinpract12050068 · Cited by 30
Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
Papavassiliou, K. A., Marinos, G., & Papavassiliou, A. G. (2023) · Cancers · doi:10.3390/cancers15020386 · Cited by 31
Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
Liu, Y., Xu, C., Han, X., Cheng, X., Jiang, S., Lin, Y., Zhang, Z., Lu, L., Qu, B., Chen, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032747 · Cited by 31
“Blocking this interaction by ICIs leads to increased T–cell activation and enhanced anti–tumor immunity (3) .”
BackgroundA review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer
Khadela, A. D., Postwala, H. I., Rana, D. K., Dave, H., Ranch, K. M., & Boddu, S. H. S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02005-w · Cited by 27
Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer
Jy, L., Bhandare, R. R., Boddu, S. H. S., SHAIK, A. B., Saktivel, L. P., Gupta, G., Negi, P., Barakat, M. M., Singh, S. K., Dua, K., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116275 · Cited by 27
Yang, Y., Shao, X., Li, Z., Zhang, L., Yang, B., Jin, B., Hu, X., Qu, X., Che, X., & Liu, Y. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18521 · Cited by 25
Zheng, H., Ning, Y., Zhan, Y., Liu, S., Yang, Y., Wen, Q., & Fan, S. (2021) · Journal of Cancer · doi:10.7150/jca.53119 · Cited by 25
Ebelt, N. D., Zuniga, E., Marzagalli, M., Zamloot, V., Blazar, B. R., Salgia, R., & Manuel, E. R. (2020) · Biomedicines · doi:10.3390/biomedicines8120617 · Cited by 22
Carvalho, Â., Ferreira, G., Seixas, D., Guimarães‐Teixeira, C., Henrique, R., Monteiro, F. J., & Jerónimo, C. (2021) · Cancers · doi:10.3390/cancers13092101 · Cited by 22
“inhibitors has been shown to improve OS of NSCLC patients in several clinical trials and is part of current clinical practice [22,23].”
BackgroundMoreno, V., Roda, D., Pikiel, J., Trigo, J. M., Bosch‐Barrera, J., Drew, Y., Kristeleit, R. S., Hiret, S., Bajor, D. L., Cruz, P., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.05.013 · Cited by 21
Holmes, M., Mahar, A. M., Lum, T., Kao, S., & Cooper, W. A. (2020) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-206709 · Cited by 20
Palaia, I., Tomao, F., Pinto, A. D., Pernazza, A., Santangelo, G., D’Alessandris, N., Manganaro, L., ARNO, A., Donato, V. D., Perniola, G., et al. (2021) · In Vivo · doi:10.21873/invivo.12379 · Cited by 20
The Proliferative Role of Immune Checkpoints in Tumors: Double Regulation
Tang, X., Luo, Z.-L., Xiong, Y., Yang, J., Shi, A., Zheng, K., Liu, Y., Shu, C., Ma, N., Lü, Q., et al. (2022) · Cancers · doi:10.3390/cancers14215374 · Cited by 24
“PD1 and PD-L1 are ubiquitous intrinsically within various tumors by immunohistochemical staining [15,16].”
BackgroundSoltani, M., Abbaszadeh, M., Fouladseresht, H., Sullman, M. J. M., & Eskandari, N. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01641-y · Cited by 28
“Specifically, in NSCLC, high PD-L1 expression is strongly related to increased tumour proliferation, aggressiveness, and decreased patient survival rates [66].”
Lee, K., Choi, Y. J., Kim, J. S., Kim, D. S., Lee, S. Y., Shin, B. K., & Kang, E. J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14006 · Cited by 20
Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic
Bian, D. J. H., Sabri, S., & Abdulkarim, B. (2022) · Cancers · doi:10.3390/cancers14153598 · Cited by 21
“Clinically, increased expression of the PD-1 ligand on cancer cells is associated with significantly worse prognosis in LC patients [55].”
BackgroundSchlicke, P., Kuttler, C., & Schumann, C. (2021) · Theoretical Biology and Medical Modelling · doi:10.1186/s12976-021-00142-1 · Cited by 19
Xu, H., Chen, X., Lin, D. X., Zhang, J., Li, C., Zhang, D., & Zhang, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s223643 · Cited by 18
“However, this relationship was not observed in patients with SCC.21 These findings suggest that the significance of PDL expression may be different between adenocarcinoma and squamous cell carcinoma.”
BackgroundChen, X., Zhang, H., Wang, M., Liu, H., Hu, Y., Tian, L., Chen, H., Zhao, M., Chen, T., Li, G., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.783695 · Cited by 18
“(28) also found that PD-L1 expression was associated with increased tumor proliferation and aggressiveness.”
BackgroundXu, H., Chen, Y., Li, Z., Zhang, H., Liu, J., & Han, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175154 · Cited by 18
Advances in the Lung Cancer Immunotherapy Approaches
Padinharayil, H., Alappat, R. R., Joy, L. M., Anilkumar, K. V., Wilson, C. M., George, A., Gopalakrishnan, A. V., Madhyastha, H., Ramesh, T., Sathiyamoorthi, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10111963 · Cited by 21
“Patients in advanced LC stages exhibit disease regression with first-line treatment, as well as the second-line choices are restricted in patients without a targetable gene mutation [3].”
BackgroundMan, R. C. H., Qiu, Y., Leung, S. W. S., Fruhwirth, G. O., & Lam, J. K. W. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114177 · Cited by 17
“PD-1/PD-L1 are one of the most widely studied immune checkpoints, and the expression of PD-L1 is significantly upregulated in NSCLC [8,9].”
Alves, M., Borges, D. D. P., Kimberly, A. S., Neto, F. M., Oliveira, A. C., de Sousa, J. C., Nogueira, C. D., Carneiro, B. A., & Tavora, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.621050 · Cited by 22
“These are in accordance to other studies that showed tumors with higher PDL1 expression with a greater tendency to necrosis, a more aggressive tumor phenotype and higher proliferation rate (39, 40).”
ResultJain, E., Sharma, S., Aggarwal, A., Bhardwaj, N., Dewan, A., Kumar, A., Jain, D. K., Bhattacharya, M., Saurav, G. K., Kini, L., et al. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153497 · Cited by 22
Tang, X., Yang, J., Shi, A., Xiong, Y., Wen, M., Luo, Z.-L., Tian, H., Zheng, K., Liu, Y., Shu, C., et al. (2022) · Cancers · doi:10.3390/cancers14225610 · Cited by 19
Neuperger, P., Balog, J. Á., Tiszlavicz, L., Furák, J., Gémes, N., Kotogány, E., Szalontai, K., Puskás, L. G., & Szebeni, G. J. (2021) · Cancers · doi:10.3390/cancers14010144 · Cited by 24
“Five additional proteins were also studied in our previous work due to their relevant functions in adenocarcinoma tumor progression and therapy resistance [27], such as carcinoma stem-cell markers: TRA-1-60 [28], CD326 (epithelial cell adhesion molecule) [29], galectin-3 (Gal-3) [30], the immune checkpoint molecule CD…”
BackgroundZheng, M., Zhou, Z., Tian, X.-T., Xiao, D., Hou, X., Xie, Z., Liang, H., & Lin, S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02627-3 · Cited by 18
Expression of PD-L1 through evolution phase from pre-invasive to invasive lung adenocarcinoma
Zhou, J., Lin, H., Ni, Z., Luo, R., Yang, D., Feng, M., & Zhang, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02310-0 · Cited by 14
Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications
Rodríguez-Lara, V., Soca‐Chafre, G., Ávila-Costa, M. R., Whaley, J. J. J., Rodríguez‐Cid, J. R., Ordóñez-Librado, J. L., Rodríguez, E., & Heredia-Jara, N. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1210297 · Cited by 16
Law, J. W., Bapat, B., Sweetnam, C., Mohammed, H., McBratney, A. E., Izano, M. A., Bryan, M. S., Spencer, S., Schroeder, B. E., Hostin, D., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00075 · Cited by 25
Kumar, M., Guleria, B., Swamy, S. S., & Soni, S. (2020) · Lung India · doi:10.4103/lungindia.lungindia_488_19 · Cited by 15
“evaluated the role of PD-L1 expression in NSCLC and their prognostic significance according to clinicopathological factors and diagnostic markers in 866 patients and reported that PD-L1 expression was seen in 42% patients with adenocarcinoma and 44% with squamous cell carcinoma.[20] Our study showed an abundance of PD…”
BackgroundResultNarits, J., Tamm, H., & Jaal, J. (2020) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2020.04.003 · Cited by 17
A call to action: molecular pathology in Brazil
da Cunha, I. W., Coudry, R. D. A., de Macêdo, M. P., de Assis, E. A. C. P., Stefani, S. D., & Soares, F. A. (2021) · Surgical and Experimental Pathology · doi:10.1186/s42047-021-00096-1 · Cited by 15
“Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, LopezRios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nichols…”
BackgroundInfluentialSnow, H. A., Mitchell, C., Hendry, S. A., McKinley, M., Byrne, D. J., Ngan, S., Chander, S., Chu, J., Desai, J., Bae, S., et al. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26261 · Cited by 13
Extracellular Vesicle Mediated Tumor-Stromal Crosstalk Within an Engineered Lung Cancer Model
Goliwas, K. F., Ashraf, H. M., Wood, A. M., Wang, Y., Hough, K. P., Bodduluri, S., Athar, M., Berry, J. L., Ponnazhagan, S., Thannickal, V. J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.654922 · Cited by 13
“PD-L1 expression by tumor cells is a well-established mechanism of immune suppression within lung tumors (40).”
BackgroundFung, S., Knoefel, W. T., & Krieg, A. H. (2021) · Cancers · doi:10.3390/cancers13164098 · Cited by 16
“Recently, expression of PD-L1 was reported to be associated with increased tumor proliferation and aggressiveness, as well as shorter survival times for patients with NSCLC [26].”
BackgroundAcheampong, E., Allsopp, R. C., Page, K., Wadsley, M. K., Beasley, A. B., Coombes, R. C., Shaw, J., & Gray, E. S. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad187 · Cited by 14
Křížová, Ľ., Benešová, I., Zemanová, P., Špaček, J., Strizova, Z. O., Humlová, Z., Mikulová, V., Petruzelka, L. B., & Vočka, M. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05628-2 · Cited by 15
“Therefore, expression of this protein is one of the most successful tumor escape mechanisms (Pawelczyk et al. 2019).”
BackgroundYoshino, H., Sato, Y., & Nakano, M. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb43010013 · Cited by 13
Wang, D., Ye, W., & Shi, Q. (2021) · Cancer Management and Research · doi:10.2147/cmar.s326189 · Cited by 12
Luca, S. D., Franco, R., Napolitano, A., Soria, V., Ronchi, A., Marino, F. Z., Corte, C. M. D., Morgillo, F., Fiorelli, A., Luciano, A., et al. (2023) · Cancers · doi:10.3390/cancers15072190 · Cited by 13
“3% with high expression levels (≥50%) [62], inversely fitting with our PATZ1 expression levels in LUSCs (Table 4).”
BackgroundBiomarkers in immunotherapy: literature review and future directions
Pharaon, R. R., Koczywas, M. A., Salgia, S. K., Mohanty, A. R., & Massarelli, E. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.04.15 · Cited by 13
Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis
Lin, X., Lin, K., Lin, C., Liu, T., Ba, M., Tang, Y., Wang, J.-L., Zhou, L., Wang, J., & Xiao, C. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107280 · Cited by 14
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model
Capitao, M., Perrin, J., Simon, S., Gouard, S., Chouin, N., Bruchertseifer, F., Morgenstern, A., Rbah‐Vidal, L., Chérel, M., Scotet, E., et al. (2021) · Cancers · doi:10.3390/cancers13061256 · Cited by 11
Shi, W., Yang, Z., Zhu, M., Zou, C., Li, J., Liang, Z., Wang, M., Yu, H., Yang, B., Wang, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.986579 · Cited by 10
“Meanwhile, it uncovered that the PD-L1 expression was correlated with gender and smoking history, and was highly correlated with tumor grade and lymph node invasion (35).”
BackgroundCHID1 Is a Novel Prognostic Marker of Non-Small Cell Lung Cancer
Kovaleva, O. V., Rashidova, M. A., Samoilova, D. V., Алексеевна, П. П., Tabiev, R. M., Mochalnikova, V. V., & Gratchev, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010450 · Cited by 11
“In addition, PD-L1 can often be found in tumor cells [22].”
Backgroundvan Duijvenvoorde, M., Derks, S., Bahce, I., Leemans, C. R., van de Ven, R., & Fransen, M. F. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1363 · Cited by 9
“In studies investigating Western populations, lower levels of PD-L1 were observed.(53) Both PD-L1 and PD-L2 are common features of ESCCs and are associated with a worst outcome.”
BackgroundAggarwal, A., Sharma, S., Brar, Z., Kumar, V. B., Akash, K., Katara, R., & Mohanty, S. K. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.155013 · Cited by 10
Batrash, F., Shaik, A., Rauf, R., Kutmah, M., & Zhang, J. (2024) · Cancers · doi:10.3390/cancers16061113 · Cited by 13
“For example, in lung cancer, programmed cell death protein 1 (PD-1) on T cells interacts with its ligand PD-L1 on cancer cells, inducing T cell exhaustion and immune suppression [22,25].”
BackgroundSalih, D. J., Barsoom, S. H., Ahmed, G. F., Hussien, S. Q., Ismaeel, Q. A., Al-Asady, A. A., Alsalim, T. A. Q., & Salih, A. M. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00018-2 · Cited by 14
“These results are in accordance with previous reports showing that IFN-γ is one of the most potent inducers of PD-L1 in NSCLC, facilitating immune escape and tumor progression (Pawelczyk et al. 2019).”
Farrag, M. S., Ibrahim, E., Abdelwahab, H. W., Elsergany, A. R., & Elhadidy, T. A. (2021) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2021.1938606 · Cited by 11
“These results are compatible with the results of Paulsen et al.[21] Also, Pawelczyk et al.[13] and Shimoji et al.[22] did not notice a correlation between PDL-1 expression and tumor stage or TNM features.”
BackgroundInfluentialZhang, R., Hohenforst‐Schmidt, W., Steppert, C., Sziklavári, Z., Schmidkonz, C., Atzinger, A., Kuwert, T., Klink, T., Sterlacci, W., Hartmann, A., et al. (2022) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-1816-6950 · Cited by 10
Emerging genetic biomarkers in lung adenocarcinoma
Barbar, J., Armach, M., Hodroj, M. H., Assi, S., Nakib, C. E., Chamseddine, N., & Assi, H. I. (2022) · SAGE Open Medicine · doi:10.1177/20503121221132352 · Cited by 10
He, J., Jiang, M., Liu, J., Zhu, R., Lv, W., Lian, R., Yang, Y., & Wang, R. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-02969-z · Cited by 12
“High expression of PD-L1 in NSCLC is implicated in poor clinical outcomes [27].”
BackgroundArak, H., Aytekin, A., Canöz, Ö., & Özkan, M. (2021) · Turkish Journal of Pathology · doi:10.5146/tjpath.2021.01545 · Cited by 12
“PD-L1 expression level and clinicopathological characteristics of the patients may be a determining factor (7).”
BackgroundMuscatello, L. V., Gobbo, F., Avallone, G., Innao, M., Benazzi, C., D’Annunzio, G., Romaniello, D., Orioles, M., Lauriola, M., & Sarli, G. (2023) · Veterinary Pathology · doi:10.1177/03009858231209410 · Cited by 15
“25,41 About 20% to 30% of non-small cell lung tumors express PDL1 in humans, 9,13,34 which is fairly close to the prevalence in our series of cases, where we observed immunolabeling in 10% of the tumors.”
BackgroundSaar, M., Narits, J., Mägi, L., Aaspõllu, H., Vapper, A., Kase, M., Minajeva, A., Vooder, T., Tamm, H., Buldakov, M., et al. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2369 · Cited by 10
Pan, L., Wang, X., Long, F., & Tang, A. (2024) · Toxicology Research · doi:10.1093/toxres/tfaf013 · Cited by 9
Association of Irisin/FNDC5 with ERRα and PGC-1α Expression in NSCLC
Nowińska, K., Jabłońska, K., Ciesielska, U., Piotrowska, A., Haczkiewicz-Leśniak, K., Pawełczyk, K., Podhorska‐Okołów, M., & Dzięgiel, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214204 · Cited by 9
“To evaluate PD-L1 expression, the Tumor Proportion Score (TPS) that is applied routinely in diagnostic settings was used (0 point < 1%, 1 point ≥ 1% to <50% and 2 points ≥ 50%) [2].”
BackgroundMethodRuiz, G., Enrico, D. H., Mahmoud, Y. D., Ruiz, A., Cantarella, M. F., Leguina, L., Barberis, M., Beña, A., Brest, E., Starapoli, S., et al. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15244 · Cited by 14
“…and clinicopathological features in NSCLC. 16 To the best of our knowledge, our study is unique and represents the largest single-region real-world cohort of a centralized PD-L1 analysis in advanced NSCLC. 30 – 33 Remarkably, the predominant subgroup observed was the PD-L1 negative category.”
BackgroundOruç, Z., Akbay, A., Ma, K., Oruç, İ., Urakçı, Z., Küçüköner, M., & Işıkdoğan, A. (2022) · Nutrition and Cancer · doi:10.1080/01635581.2022.2074064 · Cited by 8
Güven, D. C., Şahin, T. K., Erul, E., Rizzo, A., Ricci, A. D., & Yalçın, Ş. (2022) · Research Square · doi:10.21203/rs.3.rs-1785660/v1 · Cited by 8
Alishvandi, A., Aram, C., Barancheshemeh, M., Shekari, T., Firuzpour, F., & Yazdi, M. H. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00674-3 · Cited by 8
“According to previous studies, PDL-1 and LAG-3 are relevant in around 41.5% and 65.3% of NSCLC cases, respectively, while vimentin expression is noticed in approximately 45% of cases (Pawelczyk et al. 2019; Datar et al. 2019; Teocharoen et al. 2021).”
InfluentialLung Cancer Therapy: Synergistic Potential of PD-1/PD-L1 and CTLA-4 Inhibitors
Sharma, K., Saini, K., Chimaniya, P., Sahu, S., Gantayat, D., Sharma, R., Bhatt, S., & Shilpi, S. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_15 · Cited by 7
Wang, T., Fan, Z., Yue, Y., Lü, X., Deng, X., & Hou, Y. (2024) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-24-15 · Cited by 9
“…expression to be predicted noninvasively (AUCs of 0.853, 0.824, and 0.825 for the training, internal validation, and external validation sets, (22) also found that PD-L1 was expressed in 32.6% of NSCLC tumors, confirming that immune evasion is important in the early stages of lung cancer,…”
InfluentialNguyen, N. P., Page, B. R., Giap, H., Dahbi, Z., Vinh‐Hung, V., Gorobets, O., Mohammadianpanah, Μ., Motta, M., Portaluri, M. G. A., Arenas, M., et al. (2024) · Cancers · doi:10.3390/cancers16173112 · Cited by 7
Šimundža, I., Krnić, D., Juričić, J., Benzon, B., Simundza, R., Stanicic, I. M., Čapkun, V., Vukojević, K., & Durdov, M. G. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080767 · Cited by 7
“showed that PD-L1 expression seems to be associated with increased tumour proliferation and aggressiveness, as well as shorter patient survival in NSCLC, predominantly in the ADC [17].”
Background
Metadata
- Authors
- Pawelczyk, K., Piotrowska, A., Ciesielska, U., Jablonska, K., Glatzel-Plucinska, N., Grzegrzolka, J., Podhorska-Okolow, M., Dziegiel, P., & Nowinska, K.
- Affiliations
- Department of Thoracic Surgery, Wroclaw Medical University, Wroclaw 53-439, Poland
- Wroclaw Medical University (PL)
- Department of Human Morphology and Embryology, Wroclaw Medical University, Wroclaw 50-368, Poland
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-14
- Volume
- 20
- Issue
- 4
- Pages
- 824
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6413136
- OpenAlex
- W2913496992
- Cited by
- 192
- References
- 50
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 39 · 2023: 29 · 2022: 35 · 2021: 37 · 2020: 22 · 2019: 6
- FWCI
- 10.43
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Uniwersytet Medyczny im. Piastów Slaskich we Wroclawiu (ST.A110.17.037)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- PD-L1, non-small cell lung cancer, prognostic factors, tumor grade, lymph node metastasis, overall survival, lung adenocarcinoma, Ki-67, p63, TTF-1, PD-1/PD-L1 immune checkpoint, tumor cell proliferation
- MeSH terms
- Thyroid Nuclear Factor 1, Adenocarcinoma, Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Male, Membrane Proteins, Middle Aged, Prognosis, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Ki-67 Antigen, Tissue Array Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.